Evidence map›Paper›PMID 40432379›Full record

ArticleJournal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale

Role of Publicly-Funded Molecular Testing in Surgical Management of Thyroid Nodules within Canadian Medicare: Clinical Assessment of ThyroSeqv3 Molecular Test Pilot Project at McGill University.

Saruchi Bandargal, Jessica Hier, Mawaddah Abdulhaleem, Véronique-Isabelle Forest, Maryse Brassard, Geneviève Rondeau, Orr Dimitstein, Marco A Mascarella, Alex Mlynarek, Michael P Hier and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Saruchi BandargalFaculty of Medicine, McGill University, Montreal, QC, Canada.ORCID 0000-0003-3763-2119
Jessica HierDepartment of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, QC, Canada.
Mawaddah AbdulhaleemDepartment of Otolaryngology-Head and Neck Surgery, Jewish General Hospital, McGill University, Montreal, QC, Canada.
Véronique-Isabelle ForestDepartment of Otolaryngology-Head and Neck Surgery, Jewish General Hospital, McGill University, Montreal, QC, Canada.
Maryse BrassardDivision of Endocrinology, Department of Medicine, Université Laval, Centre Hospitalier Universitaire de Québec, Quebec City, QC, Canada.
Geneviève RondeauDivision of Endocrinology, Department of Medicine, Université de Montréal, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
Orr DimitsteinDepartment of Otolaryngology-Head and Neck Surgery, Jewish General Hospital, McGill University, Montreal, QC, Canada.ORCID 0009-0007-9641-5866
Marco A MascarellaDepartment of Otolaryngology-Head and Neck Surgery, Jewish General Hospital, McGill University, Montreal, QC, Canada.
Alex MlynarekDepartment of Otolaryngology-Head and Neck Surgery, Jewish General Hospital, McGill University, Montreal, QC, Canada.
Michael P HierDepartment of Otolaryngology-Head and Neck Surgery, Jewish General Hospital, McGill University, Montreal, QC, Canada.
Keith RichardsonDepartment of Otolaryngology-Head and Neck Surgery, Royal Victoria Hospital, McGill University, Montreal, QC, Canada.
Nader SadeghiDepartment of Otolaryngology-Head and Neck Surgery, Royal Victoria Hospital, McGill University, Montreal, QC, Canada.ORCID 0000-0002-3218-2668
Karen M KostDepartment of Otolaryngology-Head and Neck Surgery, Royal Victoria Hospital, McGill University, Montreal, QC, Canada.
Anthony ZeitouniDepartment of Otolaryngology-Head and Neck Surgery, Royal Victoria Hospital, McGill University, Montreal, QC, Canada.
Marc Philippe PusztaszeriDepartment of Pathology, Jewish General Hospital, McGill University, Montreal, QC, Canada.
Pierre FortierDepartment of Otolaryngology-Head and Neck Surgery, Université de Sherbrooke, Sherbrooke, QC, Canada.
Danielle BeaudoinDepartment of Otolaryngology-Head and Neck Surgery, Université Laval, Centre Hospitalier Universitaire de Québec, Quebec City, QC, Canada.
Marie-Helene MassicotteDivision of Endocrinology, Department of Medicine, Université de Montréal, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
Andree BoucherDivision of Endocrinology, Department of Medicine, Université de Montréal, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
Richard J PayneDepartment of Otolaryngology-Head and Neck Surgery, Jewish General Hospital, McGill University, Montreal, QC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ImportanceRecently, the Québec public health care system established a pilot project to cover costs of molecular testing for select patients with cytologically-indeterminate thyroid nodules.ObjectiveThis study aimed to evaluate the clinical utility of the ThyroSeqv3 molecular test pilot project at McGill University in surgical management of thyroid nodules within Canada's single-payer health care system.DesignMulticenter cohort study, in liaison with the Québec Health Ministry.SettingJewish General Hospital and Royal Victoria Hospital in Montreal, Canada.ParticipantsPatients with a Bethesda III or IV and TIRADS 3 or 4 thyroid nodule measuring between 1 and 4 cm in size on ultrasound were analyzed across pre- and post-pilot project phases.InterventionThe pre-pilot project surgical control group included patients who underwent surgical intervention, excluding those who opted for out-of-pocket molecular testing. The post-pilot project surgical exposure group encompassed participants in the pilot project, undergoing publicly-funded ThyroSeqv3 molecular testing and subsequent surgical intervention.Main Outcome MeasuresSurgical malignancy/noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) rate.ResultsA total of 314 patients qualified for the pilot project, with 207 (65.9%) having Bethesda III nodules and 107 (34.1%) having Bethesda IV nodules. Molecular testing yielded a result of negative in 238 (75.8%) cases and positive in 76 (24.2%) cases. Histopathology reports of positive patients who opted for surgery revealed a surgical malignancy/NIFTP rate of 73.1%. The surgical malignancy/NIFTP rate at our institution prior to the implementation of the pilot project for patients adhering to the inclusion criteria was statistically significantly lower at 47.9% (

Indexed as

MedicareThyroidectomyThyroid NeoplasmsThyroid NoduleAdultAgedCanadaFemaleHumansMaleMiddle AgedPilot ProjectsQuebecCanadian Medicareindeterminate thyroid nodulemolecular testingsurgical managementThyroseqv3

Identifiers

PMID40432379
PMCPMC12120268

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.